Commentary

Affiliations

¹ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
² Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
³ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Joel.Gelfand@pennmedicine.upenn.edu.

Comment

Daniel B Shin et al. J Am Acad Dermatol. 2021 Mar.

. 2021 Mar;84(3):e161-e162.

doi: 10.1016/j.jaad.2020.10.001. Epub 2020 Oct 8.

¹ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
² Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
³ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Joel.Gelfand@pennmedicine.upenn.edu.

No abstract available

Comment on

The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis.
Akiyama S, Yamada A, Micic D, Sakuraba A. Akiyama S, et al. J Am Acad Dermatol. 2021 Mar;84(3):676-690. doi: 10.1016/j.jaad.2020.08.026. Epub 2020 Aug 11. J Am Acad Dermatol. 2021. PMID: 32791083 Free PMC article.

1. Akiyama S., Yamada A., Micic D., Sakuraba A. The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84:676–690. - PMC - PubMed
1. Wan M.T., Shin D.B., Winthrop K.L., Gelfand J.M. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83:677–679. - PMC - PubMed
1. Syed M.N., Shin D.B., Wan M.T., Winthrop K.L., Gelfand J.M. The risk of respiratory tract infections in psoriasis patients treated with interleukin 23 pathway–inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83:1523–1526. - PMC - PubMed
1. Syed M.N., Shah M., Shin D.B., Wan M.T., Winthrop K.L., Gelfand J.M. Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - a meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol. 2020 doi: 10.1016/j.jaad.2020.08.095. - DOI - PMC - PubMed